About Avrobio
Avrobio is a Healthcare company based in Cambridge (United States) founded in 2016. Gene therapies for genetic diseases are developed using lentiviral technology. Avrobio has raised $85.5 million across 3 funding rounds from investors including Blackstone, Citadel and Atlas Venture. The company has 114 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Avrobio was founded in 2016 in Cambridge, United States, within the biotechnology sector. Focus is placed on gene therapies for genetic diseases, particularly lysosomal disorders. A proprietary Plato platform is utilized to create lentiviral-based treatments. The pipeline encompasses AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-05 for Hunter syndrome. Operations center on research and development in this specialized field.
- Headquarters Cambridge, United States
- Employees 114
- SectorsHealthcare
- Website avrobio.com
- Social LinkedIn X
- Net Profit-$105.89 M (USD)11as on Dec 31, 2022
- EBITDA-$105.43 M (USD)11as on Dec 31, 2022
- Total Equity Funding$85.5M (USD)
in 3 rounds
- Latest Funding Round$60.5M (USD), Series B
Feb 2018
- InvestorsBlackstone
& 8 more
- Employee Count114
Funding Insights of Avrobio
Avrobio has successfully raised a total of $85.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $60.5 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85.5M
- Total Rounds 3
- Last Round Series B — $60.5M
- Investors Count 9
All 3 funding rounds of Avrobio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2018 | $60.5M | Series B | – | Citadel | |
| Aug 2016 | $25M | Series A | – | Atlas Venture, Blackstone | – |
| Feb 2016 | Seed | – | Atlas Venture | – |
9 investors in total: 9 institutional.
Investors in Avrobio
Avrobio has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, Citadel and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Brace Pharma Capital is focused on investing in innovative therapies. | bracepharma.com | Atlanta, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Eventide Mutual Funds is managed by Eventide Asset Management, offering investment solutions. | eventidefunds.com | Boston, United States | ||
VC and private equity investments are made in China-US companies. | morningside.com.cn | Shanghai, China | ||
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States |
Investor details for Avrobio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avrobio
38 people are tracked at Avrobio (19 in leadership, 5 in board & advisors, 14 in team); the tracked headcount is 114.
| Name | Role | Group |
|---|---|---|
Hitesh Soni, Ph.D., MBA | Director, In Vivo Pharmacology/immunology | Leadership |
Anthony Muslin | Chief Development Officer | Leadership |
Rongfeng Huang, CPA, MSA | Associate Director, Accounting | Leadership |
Marc Schwabish | Chief Business Officer | Leadership |
Alise Reicin | President & CEO & Director | Leadership |
Peter McNamara | Head of Research | Leadership |
Arthur MARIVIN, PhD | Principal Scientist - Head Of Cell Biology | Leadership |
Joseph Toth | Director | Leadership |
Anthony (Tony) Muslin | Chief Development Officer | Leadership |
Kathryn Bracken | Associate Vice President, Program Management | Leadership |
John Diener | Senior Vice President | Leadership |
Yao Fan | Director, Protein Design and Optimization | Leadership |
Geraldine Peters-Wiles | Senior Vice President, People & Culture | Leadership |
Peter Marek | Director, Antibody Discovery | Leadership |
Daniel Lochner | CFO | Leadership |
Barry Rubenstein | Senior Vice President, People & Culture | Leadership |
Washington Alves | VP Of Biologics Manufacturing | Leadership |
Carl Plaut | Executive Director, Finance, Business Operations | Leadership |
Jaime Darce | Senior Director, Pharmacology | Leadership |
Terry Mcguire | Chair | Board & advisors |
18 more people are available in the full profile.
Complete people profiles for Avrobio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Avrobio
3 dated milestones of Avrobio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Avrobio is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $60.5M.
Competitors of Avrobio
Avrobio has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Avrobio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Avrobio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avrobio
Complete news archive for Avrobio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avrobio
Avrobio was founded in 2016.
Avrobio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Avrobio is a funded company, having raised a total of $85.5M across 3 funding rounds to date.
Avrobio has 114 employees.
Avrobio was founded in 2016 in Cambridge, United States, within the biotechnology sector. Focus is placed on gene therapies for genetic diseases, particularly lysosomal disorders. A proprietary Plato platform is utilized to create lentiviral-based treatments. The pipeline encompasses AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-05 for Hunter syndrome. Operations center on research and development in this specialized field.
Avrobio's top competitors include BridgeBio, Forge Biologics and Insitro.
Avrobio has 9 investors. Key investors include Blackstone, Citadel, Atlas Venture, Brace Pharma Capital, and Eventide Mutual Funds.